MentionFox
Home › Executive changes › Aligos Therapeutics, Inc.
Leadership changes · ALGS · SEC Form 8-K, Item 5.02

Leadership changes at Aligos Therapeutics, Inc. (2026)

Before you join, sell to or invest in Aligos Therapeutics, Inc.

MentionFox check on Aligos Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/aligos-therapeutics

Check Aligos Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Aligos Therapeutics, Inc.?

Who joined and who left Aligos Therapeutics, Inc. (ALGS)? 1 appointment reported on 2026-02-04, each cited to the company's own filing.

Nikhil Aneja was named Principal Accounting Officer of Aligos Therapeutics, Inc. As of November 14, 2026, Aligos Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 4, 2026, naming 1 appointment (Form 8-K, February 4, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Parkman Healthcare Partners LLC also filed stake reports on 1 other company ↓

Sell to companies like Aligos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-02-04

Aligos Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aligos Therapeutics, Inc. files it.

Also on the record for Aligos Therapeutics, Inc.

DateRecordFigureOur pageSource
November 13, 2026Stake report, Schedule 13G, by Parkman Healthcare Partners LLC5.2% of the class5%+ stakesSource
June 24, 2026Stake report, Schedule 13D, by Lawrence M. Blatt5.6% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Lawrence M. Blatt5.1% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Woodline Partners LP4.4% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Woodline Partners LP5.4% of the class5%+ stakesSource
February 11, 2026Stake report, Schedule 13G/A, by Sio Capital Management, LLC5.46% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Woodline Partners LP8.7% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by Woodline Partners LP9.8% of the class5%+ stakesSource
August 13, 2025Stake report, Schedule 13G, by Sio Capital Management, LLC5.49% of the class5%+ stakesSource
August 12, 2025Stake report, Schedule 13G/A, by Adage Capital Management, L.P.3.9% of the class5%+ stakesSource
February 28, 2025Form D, private offering$105M soldForm D pageSource

Selling to them or working with them? See who runs Aligos Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Aligos Therapeutics, Inc. and the records around it.

Aligos Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Aligos Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Aligos Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-04InPrincipal Accounting Officer8-K, 2026-02-04

Who leads Aligos Therapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Aligos Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Aligos Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Aligos Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Principal Accounting Officer at Aligos Therapeutics, Inc., with the record behind each one.

Find candidates like Principal Accounting Officer at Aligos Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-02-04 · 8-K

Appointed: Nikhil Aneja, Principal Accounting Officer

On January 29, 2026, the Board of Directors of Aligos Therapeutics, Inc. (the "Company") appointed Nikhil Aneja as the Company's Principal Accounting Officer, effective immediately.

Also stated in this filing

  • In this role, Mr. Aneja succeeds Lesley Ann Calhoun, who continues to serve as the Company's Executive Vice President, Chief Operating Officer & Chief Financial Officer.
  • Mr. Aneja, age 49, has served as the Company's Vice President, Finance since February 2024.
  • From December 2022 to February 2024, Mr. Aneja served as Vice President, Corporate Controller at CareDx, Inc., a diagnostic company.
  • Prior to that, Mr. Aneja served as Vice President, Finance and Accounting at Blade Therapeutics, Inc., a biopharmaceutical company, from May 2021 to October 2022, and as Executive Director, Global Corporate Controller at Global Blood Therapeutics, Inc., a biopharmaceutical company, from September 2016 to May 2021.
  • He received his Bachelor of Commerce from the University of Delhi and is a Certified Public Accountant.

Tools for this story

Each opens in a new tab, filled in for Aligos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/aligos-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Aligos Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/aligos-therapeutics